等待开盘 05-12 09:30:00 美东时间
0.000
0.00%
Predictive Oncology Inc. (POAI) disputes claims by Renovaro Inc. (RENB), stating they are based on inaccurate allegations. The Delaware Court of Chancery rejected RENB's request for an expedited July trial due to delays, scheduling the trial for November 12-13, 2025. POAI intends to fully defend its rights in court.
2025-05-27 12:35
Renovaro Inc. has secured an expedited trial in 2025 for its lawsuit against Predictive Oncology Inc., seeking to enforce a merger agreement. Predictive Oncology allegedly breached exclusivity and good faith provisions by conducting a securities offering and attempting to terminate the agreement. Renovaro is pursuing legal remedies to protect its shareholders' interests.
2025-05-22 19:12
Predictive Oncology Inc. leverages its large biobank of tumor samples and AI/ML platform to develop predictive tumor response models for novel drug discovery. The company's AI-driven approach, combined with real-world drug response data, accelerates early-stage drug discovery and improves success rates, positioning them as a leader in precision oncology.
2025-05-22 12:15
北京时间2025年01月17日03时19分,中进医疗(ZJYL.us)股票出现异动,股价急速上涨5.75%。截至发稿,该股报0.980美元/股,成交量17.9131万股,换手率0.11%,振幅9.23%。 最近的财报数据显示,该股实现营业收入10.56百万美元,净利润1.79百万美元,每股收益0.01美元,毛利3.74百万美元,市盈率6.29倍。 机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。 中进医疗股票所在的医疗设备行业中,整体涨幅为0.65%。其相关个股中,Predictive Oncology Inc.、Nyxoah Sa、中进医疗涨幅较大,Glucotrack, In...
2025-01-17 03:19
北京时间2024年10月03日02时37分,中进医疗(ZJYL.us)股票出现波动,股价快速上涨5.04%。截至发稿,该股报2.71美元/股,成交量11.2221万股,换手率0.07%,振幅6.59%。 最近的财报数据显示,该股实现营业收入10.56百万美元,净利润1.79百万美元,每股收益0.01美元,毛利3.74百万美元,市盈率143.01倍。 机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。 中进医疗股票所在的医疗设备行业中,整体涨幅为0.30%。其相关个股中,Innovative Eyewear, Inc.、Innovative Eyewear Inc C/Wts 16/...
2024-10-03 02:37